Skip to search formSkip to main contentSkip to account menu

Platelet Activation

Known as: blood coagulation, platelet activation, Activation, Platelet, Platelet Activations 
A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change… 
National Institutes of Health

Related topics

Related topics

48 relations
ABCC4 geneABCC4 wt AlleleBleeding time procedureBlood Platelets

Broader (1)

Blood coagulation

Narrower (1)

Platelet aggregation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Syk-driven mTOR in lymphoma-complimentary targets?
Comment on Leseux et al, page [4156][1] Leseux and colleagues report that the Syk-dependent activation of the mTOR pathway is… 
Highly Cited
1996
Highly Cited
1996
Binding of a novel 50-kilodalton alboaggregin from Trimeresurus albolabris and related viper venom proteins to the platelet membrane glycoprotein Ib-IX-V complex. Effect on platelet aggregation and…
Binding of the multimeric adhesive glycoprotein, von Willebrand Factor (vWF), to the platelet membrane glycoprotein (GP) Ib-IX-V… 
1992
1992
von Willebrand factor bound to glycoprotein Ib is cleared from the platelet surface after platelet activation by thrombin.
We recently reported that after activation of human platelets by thrombin, glycoprotein (GP) Ib-IX complexes are translocated to… 
1990
1990
R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin
We have investigated the effects of R68070 on platelet function in vitro and in vivo. The drug inhibits U46619induced aggregation… 
1987
1987
Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm.
A new calcium channel blocker, nicardipine, was studied for treatment of Raynaud's phenomenon in a double-blind, placebo… 
1986
1986
Platelet-activating factor (PAF-acether) induces high- and low-affinity binding of fibrinogen to human platelets via independent mechanisms.
When human platelets are incubated with 500 nM-PAF-acether (platelet-activating factor. 1-O-alkyl-2-acetyl-sn-glycero-3… 
1985
1985
Pulmonary platelet kinetics in asthma.
Platelets produce a range of bronchoconstrictor mediators. Measurements of plasma factors have implicated platelet activation in… 
Highly Cited
1983
Highly Cited
1983
Inhibitory effects of diltiazem on platelet activation caused by ionophore A23187 plus ADP or epinephrine in subthreshold concentrations.
We examined the effects of the slow channel Ca++ blocker diltiazem on human platelet aggregation and TXA2 generation. Diltiazem… 
1982
1982
Mediation of cardiac ischemia by thromboxanes released from human platelets.
We evaluated the consequences of platelet activation within the coronary circulation and determined the contribution of released… 
Highly Cited
1981
Highly Cited
1981
Modification of the polar head group of acetyl glyceryl ether phosphorylcholine and subsequent effects upon platelet activation.
A series of phosphoglycerides containing the same structural unit, 1-O-alkyl-2-acetyl-sn-glycerol, was prepared with the…